icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
1XSM4xC8Gw8n9W8D